Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

David Meeker, M.D., Chairman, President and Chief Executive Officer will be joined by Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine to discuss the data.

Conference Call Information

Rhythm Pharmaceuticals will host a live conference call and webcast at 9:00 a.m. ET/8:00 a.m. CT on Saturday, June 13 to discuss this update. Participants may register for the conference call here. It is recommended that participants join the call ten minutes prior to the scheduled start.